GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CervoMed Inc (NAS:CRVO) » Definitions » Cash Flow from Investing

CervoMed (CervoMed) Cash Flow from Investing : $3.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 1996. Start your Free Trial

What is CervoMed Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2024, CervoMed spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, CervoMed gained $0.00 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.


CervoMed Cash Flow from Investing Historical Data

The historical data trend for CervoMed's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CervoMed Cash Flow from Investing Chart

CervoMed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -12.24 -

CervoMed Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.50 3.00 - - -

CervoMed Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

CervoMed's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

CervoMed's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CervoMed  (NAS:CRVO) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

CervoMed's purchase of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means CervoMed spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

CervoMed's sale of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means CervoMed gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

CervoMed's purchase of business for the three months ended in Mar. 2024 was $0.00 Mil. It means CervoMed spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

CervoMed's sale of business for the three months ended in Mar. 2024 was $0.00 Mil. It means CervoMed gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

CervoMed's purchase of investment for the three months ended in Mar. 2024 was $0.00 Mil. It means CervoMed spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

CervoMed's sale of investment for the three months ended in Mar. 2024 was $0.00 Mil. It means CervoMed gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

CervoMed's net Intangibles purchase and sale for the three months ended in Mar. 2024 was $0.00 Mil. It means CervoMed paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

CervoMed's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0.00 Mil. It means CervoMed paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

CervoMed's cash from other investing activities for the three months ended in Mar. 2024 was $0.00 Mil. It means CervoMed paid $0.00 Mil for other investing activities.


CervoMed Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of CervoMed's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


CervoMed (CervoMed) Business Description

Traded in Other Exchanges
N/A
Address
20 Park Plaza, Suite 424, Boston, MA, USA, 02216
CervoMed Inc Formerly Diffusion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The company's product candidate is trans sodium crocetinate (TSC), which is used for the treatment of glioblastoma multiforme (GBM) and metastatic brain cancer. Geographically business activity of the firm functions through the region of the United States.
Executives
Frank Zavrl director C/O PUMA BIOTECHNOLOGY INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Sylvie Gregoire director, 10 percent owner 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
John William Tanner officer: Chief Financial Officer C/O EIP PHARMA, INC., 20 PARK PLAZA, SUITE 424, BOSTON MA 02116
Kelly Blackburn officer: VP, Clinical Development C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Marwan Sabbagh director C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
John J Alam director, 10 percent owner, officer: CEO and President 130 WAVERLY STREET, CAMBRIDGE MA 02139
Jeffrey V. Poulton director 300 THIRD STREET, CAMBRIDGE MA 02142
Jill Davidson director 300 EAST MAIN STREET, SUITE 101, CHARLOTTESVILLE VA 22902
Raven Jaeger officer: Chief Regulatory Officer 300 EAST MAIN STREET, SUITE 201, CHARLOTTESVILLE VA 22902
Eric Francois director C/O SCYNEXIS, INC., 3501 C TRICENTER BOULEVARD, DURHAM NC 27713
Diana M Lanchoney director 1317 CARLTON AVE, SUITE 200, CHARLOTTESVILLE VA 22902
William Robert Elder officer: GC & Secretary 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902
Cobuzzi Robert Joseph Jr. director C/O DIFFUSION PHARMACEUTICALS INC., 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902
Christopher D Galloway officer: Chief Medical Officer 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902
Jane H Hollingsworth director DIFFUSION PHARMACEUTICALS INC., 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902

CervoMed (CervoMed) Headlines

From GuruFocus

Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial

By GuruFocusNews GuruFocusNews 06-23-2022

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates DFFN, CNXC, LSI

By sperokesalga sperokesalga 04-23-2023